Antioxidant potential, paraoxonase 1, ceruloplasmin activity and C-reactive protein concentration in diabetic retinopathy
Tóm tắt
The aim of this study was to evaluate the ferric-reducing ability of serum (FRAS), paraoxonase 1 (PON1), ceruloplasmin serum oxidase activity and hsCRP level in patients with type1 diabetes mellitus without and with diabetic retinopathy. The study was performed in 76 patients with type 1 diabetes mellitus, 35 without diabetic retinopathy (group 1) and 41 with preproliferative and proliferative retinopathy (group 2). Control group consisted of 35 nondiabetic, age-, gender-, body mass-matched healthy volunteers who came to the outpatient clinic for a routine health check-up. We evaluated FRAS using the method described by Benzie and Strain; PON1 by kinetic spectrophotometric assay with paraoxon as substrate and ceruloplasmin using its oxidative activity with 3-phenylenodiamine as substrate. CRP was measured with a high sensitive enzyme immunoassay. PON1 activity was significantly decreased in patients with diabetic retinopathy (227.66 ± 123.57 U/l) when compared with control (312.04 ± 129.77 U/l). FRAS was significantly decreased in group 2 (439.33 ± 79.87 μmol/l) when compared with group 1 (522.79 ± 167.56 μmol/l) and control (529.80 ± 81.99 μmol/l). Ceruloplasmin activity was significantly elevated in group 1 (58.36 ± 22.56 U/g protein) when compared with control (45.22 ± 14.96 U/g protein). We have found significant increase in hsCRP level in group 2 (3.71 ± 2.47 mg/l) when compared with group 1 (1.75 ± 1.01 mg/l) and control (0.57 ± 0.46 mg/l). The PON1/CRP ratio in control group was significantly increased when compared with diabetic patients and was significantly decreased in group 2 compared with group 1. We have not found gender-dependent difference in studied parameters in both control and in study groups. We have found tendency to decrease the serum activity of FRAS and hsCRP in elder patients but the difference was significant only in group 2. FRAS and PON 1 activity is decreased in patients with type 1 diabetes mellitus with presence of diabetic retinopathy which confirms that oxidative stress could play a role in pathogenesis of diabetic retinopathy. Significantly elevated levels of hsCRP in diabetic patients with the presence of diabetic retinopathy compared with patients without diabetic retinopathy providing a link between inflammation and the development of microvascular complication of diabetes. Because of the significant difference in PON1/CRP ratio between patients without and with the presence of diabetic retinopathy, it seems that PON1:CRP ratio may be used as a biochemical marker for progression of retinopathy. The link between the antioxidant concentration, inflammation and the development of diabetes complications needs further longitudinal studies in order to confirm our findings.
Tài liệu tham khảo
The Diabetes Control Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Eng J Med 329:977–986
D’Amore P (1994) Mechanisms of retinal and choroidal neovascularisation. Invest Ophth Vis Sci 35:3974–3979
Nowak M, Wielkoszyński T, Marek B, Świętochowska E, Kos-Kudła B, Siemińska L, Kajdaniuk D, Głogowska-Szeląg J, Nowak K (2008) Comparison of the levels of hepatocyte growth factor in serum with grades of retinopathy in patients with type 1 diabetes mellitus. Endokrynol Pol 59:2–5
Morrish NJ, Stevens LK, Head J, Fuller JH, Jarrett RJ, Keen H (1990) A prospective study of mortality among middle-aged diabetic patients (the London Cohort of the WHO Multinational Study of Vascular Disease in Diabetics) I: causes and death rates. Diabetologia 33:538–541
Frank RN (1994) The aldose reductase controversy. Diabetes 43:169–172
Forester JV, Knott RM, Mc Intosh LC (1993) Pathogenesis of proliferative diabetic retinopathy and maculopathy. Elsevier, Amsterdam, pp 178–191
Grisanti S, Heimann K, Wiedemann P (1994) Immune response to specific molecules of the retina in proliferative vitroretinal disorders. Graefes Arch Clin Exp Ophthalmol 232:302–307
Mokini Z, Chiarelli F (2006) The molecular basis of diabetic microangiopathy. Pediatr Endocrinol Rev 4:138–152
Siemianowicz K, Gminski J, Telega A, Wójcie A, Posielezna B, Grafowska-Bochenek R, Francuz T (2004) Blood antioxidant parameters in patients with diabetic retinopathy. Int J Mol Med 14:433–437
Maiese K, Morhan SD, Chong ZZ (2007) Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitus. Curr Neurovasc Res 41:63–71
Tomas M, Latorre G, Senti M, Marrugat J (2004) The antioxidant function of high density lipoproteins: a new paradigm in atherosclerosis. Rev Esp Cardiol 57:557–569
Frieden E (1980) Caeruloplasmin: a multi-functional metalloprotein of vertebrate plasma. Ciba Found Symp 79:93–124
Healy J, Tipton K (2007) Ceruloplasmin and what it might do. J Neural Transm 114:777–781
Correale M, Brunetti ND, De Gennaro L, Di Biase M (2008) Acute phase proteins in atherosclerosis (acute coronary syndrome). Cardiovasc Hematol Agents Med Chem 6:272–277
Izuora KE, Chase HP, Jackson WE, Coll JR, Osberg IM, Gottlieb PA, Rewers MJ, Garg SK (2005) Inflammatory markers and diabetic retinopathy in type 1 diabetes. Diabetes Care 28:714–715
Benzie JF, Strain JJ (1996) The ferric reducing ability of plasma (FRAP) as a measure of „antioxidant power”: the FRAP assay. Anal Biochem 239:70–76
Eckerson HW, Romson J, Wyte C, La Du BN (1983) The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet 35:214–227
Richterich R, Temperli A, Aebi H (1962) The heterogeneity of ceruloplasmin: isolation and characterization of 2 cuproproteins from human serum. Biochim Biophys Acta 29:240–251
Nowak M, Świętochowska E, Wielkoszyński T, Marek B, Karpe J, Górski J, Głogowska-Szeląg J, Kos-Kudła B, Ostrowska Z (2003) Changes in blood antioxidants and several lipid peroxidation products in women with age-related macular degeneration. Eur J Ophthalmol 13:281–286
Chen C, Arjomandi M, Balmes J, Tanger I, Holland N (2007) Effects of chronic and acute ozone exposure on lipid peroxidation and antioxidant capacity in healthy young adults. Environ Health Perspect 115:1732–1737
Rodrigo R, Prat H, Passalacqua W, Araba J, Bachler JP (2008) Decrease in oxidative stress through supplementation of vitamins C and E is associated with a reduction in blood pressure in patients with essential hypertension. Clin Sci (Lond) 114:625–634
Jones AF, Winkles JW, Jennings PE, Florkowski CM, Lunec J, Barnett AH (1988) Serum antioxidant activity in diabetes mellitus. Diabetes Res 7:89–92
Srivatsan R, Das S, Gadde R, Manoj-Kumar K, Taduri K, Rao N, Ramesh B, Baharani A, Shah K, Kamireddy SC, Priyatham G, Balakumaran TA, Balakumaran SS, Kamath A, Rao A (2009) Antioxidants and lipid peroxidation status in diabetic patients with and without complications. Arch Iran Med 12:121–127
Memişoğullari R, Bakan E (2004) Levels of ceruloplasmin, transferrin, and lipid peroxidation in the serum of patients with Type 2 diabetes mellitus. J Diabetes Complicat 18:193–197
Abou-Seif MA, Youssef MA (2004) Evaluation of some biochemical changes in diabetic patients. Clin Chim Acta 346:161–170
Siemianowicz K, Francuz T, Gminski J, Telega A, Syzdol M (2005) Endothelium dysfunction in patients with diabetic retinopathy. Int J Mol Med 15:459–462
Ceriello A, Kumar S, Piconi L, Esposito K, Giugliano D (2007) Simultaneous control of hyperglycemia and oxidative stress normalizes endothelial function in type 1 diabetes. Diabetes Care 30:649–654
Yim S, Malhotra A, Veves A (2007) Antioxidants and CVD in diabetes: where do we stand now. Curr Diab Rep 7:8–13
Scott JA, King GL (2004) Oxidative stress and antioxidant treatment in diabetes. Ann NY Acad Sci 1031:204–213
Firoozrai M, Nourbakhsh M, Razzaghy-Azar M (2007) Erythrocyte susceptibility to oxidative stress and antioxidant status in patients with type 1 diabetes. Diabetes Res Clin Pract 77:427–432
Vander Jagt DJ, Harrison JM, Ratliff DM, Hunsaker LA, Vander Jagt DL (2001) Oxidative stress indices in IDDM subjects with and without long-term diabetic complications. Clin Biochem 34:265–270
Ashok BT, Ali R (1999) The aging paradox: free radical theory of aging. Exp Gerontol 34:293–303
Biesalski HK (2002) Free radical theory of aging. Curr Opin Clin Nutr Metab Care 5:5–10
James RW (2006) A long and winding road: defining the biological role and clinical importance of paraoxonases. Clin Chem Lab Med 44:1052–1059
Ikeda Y, Suehiro T, Inoue M, Nakauchi Y, Morita Y, Arii K, Ito H, Kumon Y, Hashimoto K (1998) Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus. Metabolism 47:598–602
Wang H, Deng H, Liu W (2002) The effects of paraoxonase-1 and oxidized low density lipoprotein on nephropathy in type-2 diabetes mellitus. Zhonghua Nei Ke Za Zhi 41:179–182
Sampson M, Braschi S, Willis G, Astley S (2005) Paraoxonase-1 (PON1) genotype and activity and in vivo oxidised plasma low density lipoprotein [oxLDL] in type 2 diabetes. Clin Sci (Lond) 109:189–197
Kordonouri O, James RW, Bennetts B, Chan A, Kao YL, Danne T, Silink M, Donaghue K (2001) Modulation by blood glucose levels of activity and concentration of paraoxonase in young patients with type 1 diabetes mellitus. Metabolism 50:657–660
Mackness B, Hine D, McElduff P, Mackness M (2006) High C-reactive protein and low paraoxonase 1 in diabetes as risk factor for coronary heart disease. Atherosclerosis 186:396–401
Schalwijk CG, Poland DC, van Dijk W, Kok A, Emeis JJ, Drager AM, Doni A, van Hinsbergh VW, Stehouwer CD (1999) Concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 42:351–357
Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U, Kociok N, Fauser S, Kirchhof B, Kern TS, Adamis AP (2004) A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 18:1450–1452
Hayaishi-Okano R, Yamasaki Y, Katakami N, Ohtoshi K, Gorogawa S, Kuroda A, Matsuhisa M, Kosugi K, Nishikawa N, Kajimoto Y, Hori M (2002) Elevated C-reactive protein associates with early-stage carotid atherosclerosis in young subjects with type 1 diabetes. Diabetes Care 25:1432–1438
Targher G, Bertolini L, Zoppini G, Zenari L, Falezza G (2005) Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in Type 1 diabetic patients without clinically manifest macroangiopathy. Diabet Med 22:999–1004
van Hecke MV, Dekker JM, Nijpels G, Moll AC, Heine RJ, Bouter LM, Polak BC, Stehouwer CD (2005) Inflammation and endothelial dysfunction are associated with retinopathy: the Hoorn Study. Diabetologia 48:1300–1306
Nowak M, Wielkoszyński T, Marek B, Kos-Kudła B, Świętochowska E, Siemińska L, Kajdaniuk D, Głogowska-Szelag J, Nowak K (2008) Blood levels of vascular cell adhesion molecule (sVCAM-1), intercellular adhesion molecule (sICAM-1) and endothelial leukocyte adhesion molecule-1 (ELAM-1) in diabetic retinopathy. Clin and Exp Med 8:159–164
Rifai N, Ridker PM (2003) Population distribution of C-reactive protein in apparently healthy men and women in the United States: implication for clinical interpretation. Clin Chem 49:666–669
Imhof A, Frohlich M, Loewel H, Helbecque N, Woodward M, Amouyel P, Lowe GD, Koenig W (2003) Distribution of C-reactive protein measured by high-sensitivity assays in apparently healthy men and women from different populations in Europe. Clin Chem 49:669–672
Yamada S, Gotoh T, Nakashima Y, Kayaba K, Ishikawa S, Nago N, Nakamura Y, Itoh Y, Kajii E (2001) Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population: Jichi Medical School Cohort Study. Am J Epidemiol 153:1183–1190
Khera A, McGuire DK, Murphy SA, Stanek HG, Das SR, Vongpatanasin W, Wians FH Jr, Grundy SM, de Lemos JA (2005) Race and gender differences in C-reactive protein levels. J Am Coll Cardiol 2:464–469